Latvia's National Health Service (NVD) has initiated an investigation into the prescription practices of diabetes medications 'Ozempic' and 'Rybelsus' after reports emerged that some patients received over 100 packages within a year, and in one extreme case, even more than 200 packages. During a meeting of the Saeima's Social and Labor Affairs Committee, representatives from the NVD revealed that they have identified at least two doctors associated with unusually high prescription volumes for these medications. This raises concerns about potential misuse or fraudulent prescribing practices in the healthcare system.

The NVD noted that if the investigations reveal that the prescriptions were made without justification or for dishonest reasons, those involved may face accountability. This could include financial repercussions, as the state may require the repayment of costs associated with the reimbursed medications, which could amount to thousands of euros. The issue highlights the need for stringent oversight and control mechanisms over medication prescriptions, particularly for high-cost drugs like 'Ozempic' and 'Rybelsus', which are critical for managing diabetes.

The concern stems from both ethical medical practice and the implications for public health funding, illustrating the delicate balance required in managing prescription medications. With the rising trend of chronic conditions, it is crucial for health authorities to maintain rigorous checks to prevent any misuse that could undermine public trust in the healthcare system. This investigation is expected to lead to the implementation of additional controls in the workflow of prescribing medications in Latvia.